Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO NASDAQ:CLRB NASDAQ:PRPH NASDAQ:UMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.80+5.7%$4.87$3.80▼$235.98$5.66M1.6834,047 shs20,964 shsCLRBCellectar Biosciences$2.48+1.2%$2.85$2.20▼$12.00$19.58M0.52169,608 shs101,034 shsPRPHProPhase Labs$0.08-3.0%$0.11$0.07▼$6.66$453K0.09242,793 shs144,549 shsUMRXCogent Biosciences$36.95+3.7%$10.50$0.29▼$3.72$1.57B3.931.22 million shs2.23 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+5.73%+1.69%+3.67%+6.67%-90.54%CLRBCellectar Biosciences+1.22%+9.73%-21.02%-22.01%-76.48%PRPHProPhase Labs-2.97%-21.67%-31.64%-6.82%-97.85%UMRXCogent Biosciences0.00%0.00%0.00%+7.51%+393.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.80+5.7%$4.87$3.80▼$235.98$5.66M1.6834,047 shs20,964 shsCLRBCellectar Biosciences$2.48+1.2%$2.85$2.20▼$12.00$19.58M0.52169,608 shs101,034 shsPRPHProPhase Labs$0.08-3.0%$0.11$0.07▼$6.66$453K0.09242,793 shs144,549 shsUMRXCogent Biosciences$36.95+3.7%$10.50$0.29▼$3.72$1.57B3.931.22 million shs2.23 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+5.73%+1.69%+3.67%+6.67%-90.54%CLRBCellectar Biosciences+1.22%+9.73%-21.02%-22.01%-76.48%PRPHProPhase Labs-2.97%-21.67%-31.64%-6.82%-97.85%UMRXCogent Biosciences0.00%0.00%0.00%+7.51%+393.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 2.33HoldN/AN/ACLRBCellectar Biosciences 2.50Moderate Buy$11.00343.55% UpsidePRPHProPhase Labs 1.00SellN/AN/AUMRXCogent Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APVO, PRPH, UMRX, and CLRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/26/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/15/2026CLRBCellectar Biosciences LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/8/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/5/2026CLRBCellectar Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/24/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/20/2026CLRBCellectar Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo TherapeuticsN/AN/AN/AN/A$17.42 per shareN/ACLRBCellectar BiosciencesN/AN/AN/AN/A$1.89 per shareN/APRPHProPhase Labs$5.06M0.09N/AN/A$2.46 per share0.03UMRXCogent Biosciences$22.50M69.74N/AN/A$1.04 per share35.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$25.97M-$197.60N/AN/AN/AN/A-198.50%-117.06%8/10/2026 (Estimated)CLRBCellectar Biosciences-$21.79M-$6.66N/AN/AN/AN/A-349.24%-153.18%8/13/2026 (Estimated)PRPHProPhase Labs-$53.36M-$3.90N/AN/AN/A-825.01%-482.05%-88.90%6/18/2026 (Estimated)UMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/ALatest APVO, PRPH, UMRX, and CLRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CLRBCellectar Biosciences-$1.8850-$1.33+$0.5550-$1.33$8.00 millionN/A5/13/2026Q1 2026APVOAptevo Therapeutics-$6.41-$6.41N/A-$6.41N/AN/A3/26/2026Q4 2025APVOAptevo Therapeutics-$8.10$118.23+$126.33$118.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A3.363.36CLRBCellectar BiosciencesN/A1.901.90PRPHProPhase Labs0.140.140.14UMRXCogent Biosciences0.182.902.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CLRBCellectar Biosciences16.41%PRPHProPhase Labs9.45%UMRXCogent Biosciences26.39%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.08%CLRBCellectar Biosciences2.58%PRPHProPhase Labs9.60%UMRXCogent Biosciences31.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics501.25 million1.25 millionNot OptionableCLRBCellectar Biosciences107.99 million7.79 millionNo DataPRPHProPhase Labs1306.02 million5.44 millionOptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableAPVO, PRPH, UMRX, and CLRB HeadlinesRecent News About These CompaniesCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 ...May 30, 2026 | markets.businessinsider.comCogent Bio granted FDA priority review for lead asset in tumor indicationMay 28, 2026 | seekingalpha.comCogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO ...April 21, 2026 | markets.businessinsider.comCogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)April 1, 2026 | markets.businessinsider.comCogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)March 16, 2026 | markets.businessinsider.comCogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 BreakthroughFebruary 17, 2026 | fool.comCogent Biosciences submits NDA for bezuclastinib in NONADVSMDecember 30, 2025 | msn.comCogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic MastocytosisDecember 30, 2025 | tmcnet.comCogent Biosciences: Time For A PauseDecember 15, 2025 | seekingalpha.comCogent Biosciences price target raised to $48 from $45 at JefferiesDecember 8, 2025 | msn.comCogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosisDecember 8, 2025 | msn.comCogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)December 8, 2025 | markets.businessinsider.comCogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American ...December 6, 2025 | tmcnet.comHC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy RecommendationNovember 14, 2025 | msn.comCogent Biosciences price target raised to $50 from $21 at H.C. WainwrightNovember 13, 2025 | msn.comCogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.November 13, 2025 | managedhealthcareexecutive.comMCogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.November 13, 2025 | managedhealthcareexecutive.comMCogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes ...November 11, 2025 | caledonianrecord.comCCogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDANovember 11, 2025 | biospace.comBCogent Biosciences Stock Surges 136%. Investors See Promise in Its Cancer Drug.November 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, PRPH, UMRX, and CLRB Company DescriptionsAptevo Therapeutics NASDAQ:APVO$4.80 +0.26 (+5.73%) Closing price 06/17/2026 04:00 PM EasternExtended Trading$4.79 -0.01 (-0.21%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Cellectar Biosciences NASDAQ:CLRB$2.48 +0.03 (+1.22%) Closing price 06/17/2026 04:00 PM EasternExtended Trading$2.49 +0.01 (+0.40%) As of 05:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.ProPhase Labs NASDAQ:PRPH$0.08 0.00 (-2.97%) As of 06/17/2026 03:56 PM EasternProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Cogent Biosciences NASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
